What considerations should be taken when using the PCE to estimate 10-year ASCVD risk?
The PCE are best validated among non-Hispanic whites and non-Hispanic blacks living in the United States. Therefore, clinicians may consider the use of another risk prediction tool as an alternative to the PCE if the tool was validated in a population with characteristics similar to those of the evaluated patient. For adults >75 years of age, the clinician and patient should engage in a discussion about the possible benefits of preventive therapies appropriate to the age group in the context of comorbidities and life expectancy.